After Januvia And Onglyza, Novartis Launches Galvus In China; Lucentis Receives SFDA Nod
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis looks to take on Merck’s Januvia in China, noting it will have a level-playing field despite playing catch up in the market with the world’s largest diabetes population.
You may also be interested in...
Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis
Regeneron has designed the launch strategy of its bimonthly wet AMD injection Eylea to head off any reimbursement issues.
Sanofi China GM Fabrice Baschiera On Winning The Insulin Battle In China: An Interview With PharmAsia News (Part 1 of 2)
Sanofi SA China Pharmaceutical Operations General Manager Fabrice Baschiera spent more than eight years in Asia working for Sanofi's Asia operations in South Korea, Thailand and Vietnam before he moved to China last August.
Lucentis Shines In Diabetic Eye Disease, But Competition Looms From Cheap, Off-Label Avastin
Full details on the pivotal RISE and RIDE trials in diabetic macular edema at ADA meeting show that the drug improves vision and halts disease progression, paving way for FDA filing this fall.